WallStSmart

Chevron Corp (CVX)vsNovo Nordisk A/S (NVO)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Novo Nordisk A/S generates 67% more annual revenue ($309.06B vs $184.65B). NVO leads profitability with a 33.1% profit margin vs 6.7%. CVX appears more attractively valued with a PEG of 3.82. NVO earns a higher WallStSmart Score of 55/100 (C).

CVX

Hold

40

out of 100

Grade: F

Growth: 2.0Profit: 5.0Value: 4.7Quality: 3.5
Piotroski: 1/9

NVO

Buy

55

out of 100

Grade: C

Growth: 4.0Profit: 10.0Value: 4.7Quality: 4.8
Piotroski: 3/9Altman Z: 2.08
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CVXSignificantly Overvalued (-358.0%)

Margin of Safety

-358.0%

Fair Value

$45.15

Current Price

$205.15

$160.00 premium

UndervaluedFair: $45.15Overvalued
NVOSignificantly Overvalued (-59.4%)

Margin of Safety

-59.4%

Fair Value

$24.21

Current Price

$36.33

$12.12 premium

UndervaluedFair: $24.21Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CVX3 strengths · Avg: 8.7/10
Market CapQuality
$403.33B10/10

Mega-cap, among the largest globally

Price/BookValuation
2.2x8/10

Reasonable price relative to book value

Free Cash FlowQuality
$5.38B8/10

Generating 5.4B in free cash flow

NVO5 strengths · Avg: 9.8/10
P/E RatioValuation
10.4x10/10

Attractively priced relative to earnings

Return on EquityProfitability
60.7%10/10

Every $100 of equity generates 61 in profit

Profit MarginProfitability
33.1%10/10

Keeps 33 of every $100 in revenue as profit

Operating MarginProfitability
44.5%10/10

Strong operational efficiency at 44.5%

Market CapQuality
$165.02B9/10

Large-cap with strong market position

Areas to Watch

CVX4 concerns · Avg: 3.3/10
P/E RatioValuation
30.4x4/10

Premium valuation, high expectations priced in

Return on EquityProfitability
7.2%3/10

ROE of 7.2% — below average capital efficiency

Profit MarginProfitability
6.7%3/10

6.7% margin — thin

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

NVO4 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
4.882/10

Expensive relative to growth rate

Revenue GrowthGrowth
-7.6%2/10

Revenue declined 7.6%

EPS GrowthGrowth
-4.7%2/10

Earnings declined 4.7%

Comparative Analysis Report

WallStSmart Research

Bull Case : CVX

The strongest argument for CVX centers on Market Cap, Price/Book, Free Cash Flow.

Bull Case : NVO

The strongest argument for NVO centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 33.1% and operating margin at 44.5%.

Bear Case : CVX

The primary concerns for CVX are P/E Ratio, Return on Equity, Profit Margin.

Bear Case : NVO

The primary concerns for NVO are Piotroski F-Score, PEG Ratio, Revenue Growth.

Key Dynamics to Monitor

CVX profiles as a value stock while NVO is a declining play — different risk/reward profiles.

CVX carries more volatility with a beta of 0.66 — expect wider price swings.

NVO is growing revenue faster at -7.6% — sustainability is the question.

CVX generates stronger free cash flow (5.4B), providing more financial flexibility.

Bottom Line

NVO scores higher overall (55/100 vs 40/100), backed by strong 33.1% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Chevron Corp

ENERGY · OIL & GAS INTEGRATED · USA

Chevron Corporation is an American multinational energy corporation. One of the successor companies of Standard Oil, it is headquartered in San Ramon, California, and active in more than 180 countries. Chevron is engaged in every aspect of the oil and natural gas industries, including hydrocarbon exploration and production; refining, marketing and transport; chemicals manufacturing and sales; and power generation.

Novo Nordisk A/S

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.

Want to dig deeper into these stocks?